European Commission greenlights $16.5B Novo-Catalent acquisition 

De­spite months of bio­phar­ma in­dus­try push­back, the Eu­ro­pean Com­mis­sion has un­con­di­tion­al­ly ap­proved No­vo Hold­ings’ $16.5 bil­lion ac­qui­si­tion of Catal­ent.

The Fed­er­al Trade …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.